Literature DB >> 21665304

Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression.

Kristin Gurtner1, Yvonne Deuse, Rebecca Bütof, Katja Schaal, Wolfgang Eicheler, Reinhard Oertel, Reidar Grenman, Howard Thames, Ala Yaromina, Michael Baumann, Mechthild Krause.   

Abstract

PURPOSE: To compare functional effects of combined irradiation and EGFR inhibition in different HNSCC tumour models in vivo with the results of molecular evaluations, aiming to set a basis for the development of potential biomarkers for local tumour control.
MATERIAL AND METHODS: In five HNSCC tumour models, all wild-type for EGFR and KRAS, the effect of radiotherapy alone (30 fractions/6 weeks) and with simultaneous cetuximab or erlotinib treatment on local tumour control were evaluated and compared with molecular data on western blot, immunohistochemistry and fluorescence-in situ-hybridisation (FISH).
RESULTS: Erlotinib and cetuximab alone significantly prolonged tumour growth time in 4/5 tumour models. Combined irradiation and cetuximab treatment significantly improved local tumour control in 3/5 tumour models, whereas erlotinib did not alter local tumour control in any of the tumour models. The amount of the cetuximab-effect on local tumour control significantly correlated with the EGFR/CEP-7 ratios obtained by FISH.
CONCLUSION: Both drugs prolonged growth time in most tumour models, but only application of cetuximab during irradiation significantly improved local tumour control in 3/5 tumour models. The significant correlation of this curative effect with the genetic EGFR expression measured by FISH will be further validated in preclinical and clinical studies.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21665304     DOI: 10.1016/j.radonc.2011.05.035

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  28 in total

1.  [RTOG study 0324: Cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer].

Authors:  C Nieder
Journal:  Strahlenther Onkol       Date:  2012-02       Impact factor: 3.621

2.  Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers.

Authors:  Qi Liu; Meng Wang; Ashley M Kern; Saman Khaled; Jing Han; Beow Y Yeap; Theodore S Hong; Jeff Settleman; Cyril H Benes; Kathryn D Held; Jason A Efstathiou; Henning Willers
Journal:  Mol Cancer Res       Date:  2015-02-09       Impact factor: 5.852

Review 3.  [Experimental tumor therapy].

Authors:  M Baumann; D Zips; M Krause
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

4.  Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.

Authors:  M Saki; M Toulany; W Sihver; M Zenker; J-M Heldt; B Mosch; H-J Pietzsch; M Baumann; J Steinbach; H P Rodemann
Journal:  Strahlenther Onkol       Date:  2012-08-10       Impact factor: 3.621

Review 5.  Improving external beam radiotherapy by combination with internal irradiation.

Authors:  A Dietrich; L Koi; K Zöphel; W Sihver; J Kotzerke; M Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-03-18       Impact factor: 3.039

Review 6.  [Concurrent radiochemotherapy for the treatment of solid tumors].

Authors:  R Fietkau
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

Review 7.  Individualization of cancer treatment from radiotherapy perspective.

Authors:  Ala Yaromina; Mechthild Krause; Michael Baumann
Journal:  Mol Oncol       Date:  2012-02-09       Impact factor: 6.603

8.  Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo.

Authors:  Kristin Gurtner; Zofia Kryzmien; Lydia Koi; Meng Wang; Cyril H Benes; Sandra Hering; Henning Willers; Michael Baumann; Mechthild Krause
Journal:  Int J Cancer       Date:  2019-08-19       Impact factor: 7.396

9.  Epidermal growth factor receptor targeted nuclear delivery and high-resolution whole cell X-ray imaging of Fe3O4@TiO2 nanoparticles in cancer cells.

Authors:  Ye Yuan; Si Chen; Tatjana Paunesku; Sophie Charlotte Gleber; William C Liu; Caroline B Doty; Rachel Mak; Junjing Deng; Qiaoling Jin; Barry Lai; Keith Brister; Claus Flachenecker; Chris Jacobsen; Stefan Vogt; Gayle E Woloschak
Journal:  ACS Nano       Date:  2013-11-27       Impact factor: 15.881

10.  Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models.

Authors:  Hanneke Stegeman; Johannes H Kaanders; Albert J van der Kogel; Mari Iida; Deric L Wheeler; Paul N Span; Johan Bussink
Journal:  Radiother Oncol       Date:  2013-02-28       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.